BioSpace News Archive

KEDPLASMA, a leader in the collection of highquality plasma, is proud to announce a comprehensive remodeling initiative aimed at enhancing the experience of its donors and raising the standard of excellence in its collection centers.

IDEAYA Biosciences, Inc. announced its participation in the Jefferies London Healthcare Conference and its plans to host an Investor R&D Day in December 2023.

Heartseed Inc., a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure and I Peace Inc., a leading GMP cell CDMO in Palo Alto, California, have collaborated to generate cardiomyocytes using multiple donor-derived iPS cell lines produced by I Peace and Heartseed’s proprietary cardiomyocytes differentiation and purification methods.

Generate:Biomedicines and Roswell Park Comprehensive Cancer Center announced a strategic collaboration to discover and develop chimeric antigen receptor T-cell therapies, and armoring technologies, for up to three oncology targets, including in ovarian cancer and other solid tumors.

United Therapeutics Corporation, a public benefit corporation, announced its financial results for the quarter ended September 30, 2023.

LivaNova PLC, a market-leading medical technology company, reported results for the quarter ended September 30, 2023 and raised full-year 2023 revenue and adjusted diluted earnings per share guidance.

G1 Therapeutics, Inc., a commercial-stage oncology company, provided a corporate and financial update for the third quarter ended September 30, 2023.

Oculis Holding AG announced that the positive results from Stage 1 of its Phase 3 DIAMOND trial of OCS-01 in patients with diabetic macular edema, will be presented as a late-breaking abstract at the American Academy of Ophthalmology 2023 Annual Meeting, taking place Friday, November 3, 2023 through Monday, November 6, 2023 in San Francisco, California.

Affimed N.V. announced that the Company’s management will participate in the following investor conferences during the month of November 2023.

Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, reported financial results for the third quarter ended September 30, 2023 and provided key pipeline and business updates.